Aura Biosciences, Inc. (AURA)

7.31 -0.23 (-3.05%) At close: 04:00PM EDT

Aura Biosciences, Inc.

80 Guest Street
5th Floor
Boston, MA 02135
United States
617 500 8864
https://www.aurabiosciences.com

Sector(s): Healthcare
Industry: Biotechnology
Full-time employees: 88

Key executives

Name	Title	Pay	Exercised	Year born
Dr. Elisabet de los Pinos Ph.D.	Founder, CEO, President & Director	895.16k	N/A	1974
Ms. Julie B. Feder	Chief Financial Officer	604.2k	N/A	1971
Dr. Mark Plavsic D.V.M., Ph.D.	Chief Technology Officer	N/A	N/A	1961
Mr. Conor Kilroy	General Counsel & Secretary	N/A	N/A	1982
Mr. Patrick Nealon	Senior Vice President of Clinical Development Operations	N/A	N/A	N/A
Dr. Bruce Brown M.D.	Senior VP & Therapeutic Area Head of Urologic Oncology	N/A	N/A	N/A
Dr. Anthony Daniels M.D.	Therapeutic Area Head of Ocular Oncology	N/A	N/A	N/A
Dr. Richard Mountfield Ph.D.	Senior Vice President of Regulatory Affairs & Quality	N/A	N/A	N/A
Dr. Jill J. Hopkins M.D.	Chief Medical Officer & President of Research and Development	N/A	N/A	1965

Amounts are as of 31 December 2023, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Aura Biosciences, Inc., a clinical-stage biotechnology company, develops precision immunotherapies to treat a range of solid tumors. The company's proprietary platform enables the targeting of a range of solid tumors using virus-like particles conjugated with drugs or loaded with nucleic acids to create virus-like drug conjugates. Its lead candidate is bel-sar, which is in late-stage clinical development for the treatment of patients with primary choroidal melanoma and other ocular oncology indications, as well as in early-stage clinical development in bladder cancer. The company also focuses on assessing the safety and efficacy of bel-sar in treating a range of other solid tumors, including bladder cancer as an alternative to bacillus calmette–guérin therapy. Aura Biosciences, Inc. was incorporated in 2009 and is headquartered in Boston, Massachusetts.

Corporate governance

Aura Biosciences, Inc.’s ISS governance QualityScore as of 1 May 2024 is 7. The pillar scores are Audit: 8; Board: 7; Shareholder rights: 8; Compensation: 7.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.